Scientists from The University of Manchester have shown that testing for two gene families linked to a lifetime epithelial ovarian cancer risk of between 5% and 20% has a much higher than expected detection rate.
Oct 4, 2022
0
13
The ongoing fight of science against cancer has made great strides, but cancer cells have not made it easy. The complexity of cancer cells and their adaptive evolutionary nature complicate the search for effective cures. ...
Feb 16, 2021
0
15
Scientists at the Francis Crick Institute, in collaboration with Artios, have identified how an enzyme involved in DNA repair (POLQ), becomes vital to the survival of certain cancers, if the cancer cells lose the ability ...
Nov 30, 2022
0
68
Researchers have developed a first-of-its- kind system to observe repair to broken DNA in newly synthesized telomeres, an effort which has implications for designing new cancer drugs.
Oct 19, 2016
0
14
New insights into the mechanisms behind how cancer-causing agents in the environment activate genetic recombination in DNA could help to explain some of the effects of exposure as well as predicting which individuals may ...
Nov 17, 2020
0
62
Treatments that harness the immune system to fight cancer have greatly improved outcomes for some people with cancer. Scientists are learning more about why some people respond much better than others to these drugs.
Dec 1, 2020
0
71
A protein that cancer cells rely on to stave off cell death also helps them regulate DNA repair, researchers at Winship Cancer Institute of Emory University (Winship) have discovered.
Jan 3, 2018
0
26
A combination of the PARP inhibitor olaparib (Lynparza) and the investigational ATR inhibitor ceralasertib showed clinical benefit in pediatric patients with solid tumors exhibiting DNA replication stress and/or DNA repair ...
Apr 18, 2023
0
9
Researchers from The University of Texas MD Anderson Cancer Center reported study results showing that initial treatment with the PARP inhibitor veliparib in combination with chemotherapy significantly increased progression-free ...
Sep 28, 2019
0
6
A new research paper titled "LP-284, a small molecule acylfulvene, exerts potent antitumor activity in preclinical non-Hodgkin's lymphoma models and in cells deficient in DNA damage repair" has been published in Oncotarget.
Jun 12, 2023
0
27
